BiotechTube
Home/LoQus23 Therapeutics/Dr. David Reynolds
DD

Dr. David Reynolds

Chief Executive Officer & Co-founder

LoQus23 Therapeutics

Therapeutic Areas

NeurologyRare Diseases

LoQus23 Therapeutics Pipeline

DrugIndicationPhase
Somatic Expansion Inhibitor ProgramHuntington's DiseasePreclinical
Platform ExpansionOther Triplet Repeat Expansion DisordersResearch

Leadership Team at LoQus23 Therapeutics

DC
Dr. Caroline Benn
Chief Scientific Officer & Co-founder
DD
Dr. David Hardick
Head of Chemistry
DA
Dr. Amanda Davis
VP of Operations and Development
DT
Deb Tonge
Finance Director
DC
Dr. Cyrus Mozayeni
Chair of the Board
View full LoQus23 Therapeutics profile